Journal Club- "Eteplirsen in the treatment of Duchenne muscular dystrophy"
This course was designed because new patients and their families have questions about Eteplirsen and the Infusion center nurses only have a very basic understanding of how the medication works
After completing this activity, the learner will be able to:
- Discuss the pros and cons of Eteplirsen (Exondys 51) and the controversy surrounding it's approval.
- Describe the mutation(s) responsible for DMD (Duchenne muscular dystrophy) and how exon skipping medications work.
Conflict of Interest Disclosure:
No planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
- 1.00 ANCCUPMC Provider Unit is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
- 1.00 Attendance